REcanalization of Distal Cerebral Vessels In Acute Stroke Using ApeRio®
Last updated on July 2021Recruitment
- Recruitment Status
- Active, not recruiting
- Estimated Enrollment
- Same as current
Summary
- Conditions
- Acute Stroke
- Design
- Observational Model: CohortTime Perspective: Prospective
Participation Requirements
- Age
- Between 18 years and 125 years
- Gender
- Both males and females
Description
Study Type: prospective, multicenter, single-arm, open-label Participants: 10 participating centers in Germany planned PI: Dr. Franziska Dorn, University Hospital Munich, Germany Estimated Enrolment: A minimum of 130 patients treated with the Aperio® or Aperio® Thrombectomy Device due to thrombotic ...
Study Type: prospective, multicenter, single-arm, open-label Participants: 10 participating centers in Germany planned PI: Dr. Franziska Dorn, University Hospital Munich, Germany Estimated Enrolment: A minimum of 130 patients treated with the Aperio® or Aperio® Thrombectomy Device due to thrombotic occlusion of the anterior or posterior circulation arteries with a diameter <3mm Follow up: 3 months Estimated Final Assessment: End of 2022 This is a prospective, multicenter, single-arm, open-label, national Post-Market Clinical Follow-up Study to collect comprehensive information on technical and clinical success and safety of the use of Aperio® and Aperio® Hybrid Thrombectomy Device in arteries <3mm in clinical practice. Aperio® and Aperio® Hybrid Thrombectomy Device will be used within its approved indication.
Tracking Information
- NCT #
- NCT04479020
- Collaborators
- Not Provided
- Investigators
- Not Provided
Get Well Soon